Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05073692 · ClinicalTrials.gov registry record
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
A clinical trial, sponsored by Kaiser Permanente.
- Completed
- Registry status
- 241,981
- Enrollment target
NCT05073692: Completed study, sponsored by Kaiser Permanente.
NCT05073692 is a clinical trial that has completed, run by Kaiser Permanente. The registered enrollment target is 241,981 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05073692 has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- 241,981 participants
- Enrollment target
Study Summary
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.
Primary Outcome
3-point MACE is defined as a single outcome measure, which is a composite measure of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular disease death.
Interventions
- DRUG GLP-1RA
- DRUG SGLT2i
- DRUG SU
- DRUG DPP4
- DRUG SGLT2i or GLP-1RA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241,981 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2025-03-12 |
What the finished NCT05073692 record still lists
NCT05073692 is an observational study that tracks outcomes without assigning an intervention. Its 241,981 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 5 interventions - of which GLP-1RA is the first listed.
NCT05073692 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05073692 about?
NCT05073692 is a clinical study titled "Comparison of Type 2 Diabetes Pharmacotherapy Regimens". This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication...
What is the current status of trial NCT05073692?
This trial is currently completed. The enrollment target is 241,981 participants. The study started on 2021-07-01. Estimated completion is 2025-03-12.
What interventions are being tested in trial NCT05073692?
The interventions under investigation include: GLP-1RA (DRUG), SGLT2i (DRUG), SU (DRUG), DPP4 (DRUG), SGLT2i or GLP-1RA (DRUG).
Who is sponsoring clinical trial NCT05073692?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT06694181 · 300,000 participants
Safe and Explainable AI
- NCT07314697 · 300,000 participants · NA
Arrival Time Implementation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI